Track the VERMILLION, INC. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on US US, under the supervision of SEC (Form 4). Market capitalisation: €1.8bn. The latest transaction was filed on 1 February 2016 (Acquisition). Among the most active insiders: SCHULER JACK W. The full history is free.
9
Insider Decl.
0
Thresholds
·
9 ops.
Buy Volume
·
0 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate VERMILLION, INC. Strong Buy (bullish), based on 10 analysts. Average price target: US$57.10.
2Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 18,985 of 25,804 companies
35.9
score / 100
Value
26
Quality
46
FCF yld-4.9%
Earn yld-0.6%
EV/EBITDA·
ROE-28%
Gross mgn64%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
57,749 sharesCommon Stock, par value $0.001 per shareSEC:0001140361-16-048188:1
Ideal exit: 15 Oct 2016 (T+270)
9 of 9 declarations
About VERMILLION, INC.
VERMILLION, INC. is a company listed on the XNAS market, specializing in the development of diagnostic solutions for women's health-related diseases. It focuses on innovation in the field of diagnostic testing.